Gene name: transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)
# |
PMID |
Sentence |
1 |
8438562
|
The mutants were assessed for their ability to bind E2a, E2b, and E2c MAbs in an enzyme-linked immunosorbent assay, to induce fatal disease in neonatal mice following subcutaneous or intracranial inoculation and to compete with wild-type virus for binding to unfractionated neonatal mouse brain cells.
|
2 |
8438562
|
None of the substitutions affected binding of E2a or E2b MAbs, and decreased binding to E2c MAbs was correlated with decreased virulence in neonatal mice.
|
3 |
8438562
|
The mutants were assessed for their ability to bind E2a, E2b, and E2c MAbs in an enzyme-linked immunosorbent assay, to induce fatal disease in neonatal mice following subcutaneous or intracranial inoculation and to compete with wild-type virus for binding to unfractionated neonatal mouse brain cells.
|
4 |
8438562
|
None of the substitutions affected binding of E2a or E2b MAbs, and decreased binding to E2c MAbs was correlated with decreased virulence in neonatal mice.
|
5 |
11544306
|
A panel of E2 DNA vaccines were constructed, and their vaccination efficacy was ranked as E2 > tyrosine kinase-deficient ErbB-2 (E2A) > full-length ErbB-2 targeted to the cytoplasm (cytE2) > tyrosine kinase-deficient cytE2 (cytE2A).
|
6 |
11544306
|
Covaccination with cytE2A and GM-CSF or IL-2 DNA resulted in equivalent anti-tumor activity as E2.
|
7 |
11544306
|
ErbB-2-specific CTL were detected in mice immunized with cytE2A and GM-CSF and have rejected tumor challenge.
|
8 |
11544306
|
Depletion of CD8, but not CD4 T cells reduced anti-tumor immunity, indicating CTL as the effector cells.
|
9 |
15826912
|
However, mutant PAdV-3s containing deletion including authentic E1A promoter region, displayed both reduced steady-state levels of early gene mRNAs (E1A, E1B, E2A, E3, and E4) and decreased rate of viral replication in ST cells.
|
10 |
15996480
|
Our preliminary results in humans indicate similar reductions: we show herein that the expression of E2A and AID progressively decline with age.
|
11 |
18390709
|
Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells.
|
12 |
18390709
|
Our results obtained with activated CD19(+) B cells show that the expression of E47, AID, and Iggamma1 circle transcripts progressively decrease with age.
|
13 |
18390709
|
We also show an age-related decline in the percentage of switch memory B cells (IgG(+)/IgA(+)), an increase in that of naive B cells (IgG(-)/IgA(-)/CD27(-)) for most individuals, and no decrease in that of IgM memory cells in peripheral blood, consistent with our data on the decrease seen in class switch recombination in vitro.
|